Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

NCT06532084 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse
Myelodysplastic Syndromes
Chronic Myeloid Leukemia
Myeloproliferative Neoplasm

Interventions

DRUG: Sorafenib

Sponsor

St. Petersburg State Pavlov Medical University